A technology for delivering a standardised therapeutic dosage of plasma for treatment of COVID-19 patients so that just the right amount of dose is administered to the patient. The Lyophilised - COVID Antibody Rich Product (L-CARP) have developed a safe therapy and avoids transmission of infections by a strategic donor with the help of a screening process. They have developed a bank of L-CARP, to avoid the delay and hassle of finding, screening and withdrawing the plasma at the last minute.
Accessibility Controls